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ABSTRACT
Introduction: Inhaled therapies are likely to continue to dominate asthma and chronic obstructive
pulmonary disease treatment. Dry powder inhalers (DPIs) have several advantages over pressurized
metered-dose inhaler (pMDIs), that are most frequently marketed world-wide, but often difficult to use.
This literature search focus on DPI features, with respect to Easyhaler, that may affect their use and
patients’ clinical benefit.
Areas covered: DPIs are breath-actuated, easy to use, convenient to use, and more environmentally
friendly. During inhalation, the formulation in a DPI is disaggregated by a turbulent airflow energy to
generate particles with the greatest likelihood of deposition into the airways. The resistance among DPIs
varies from low to high and those with high resistance are wrongly considered as difficult to use. Multidose
reservoir-type DPIs have been developed to efficiently deliver a wide range of medications, including the
fixed-dose combination of budesonide and formoterol. Easyhaler® shares a similar shape with pMDIs and, as
other DPIs, its performance is unaffected by environmental and storage conditions. Due to Easyhaler
internal design, dose emission is consistent irrespective of the inhalation flow used by each patient.
Expert opinion: Easyhaler® may be considered one of the most convenient inhalers, for daily use, in
patients with asthma or COPD.
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The main goals of pharmacological therapy for asthma,
chronic obstructive pulmonary disease (COPD), and asthma/
COPD overlap (ACO) are to control symptoms, reduce the
frequency and severity of exacerbations, improve exercise
tolerance and the health status, and reduce mortality. These
goals can be reached by following new relevant recommenda-
tions from the updated GINA guidelines, e.g. the avoidance of
SABA-only treatment and an ICS-containing controller treat-
ment, either as-needed (in mild asthma) or daily [1,2]. Since
medications are frequently administrated by inhalation and
numerous inhaler devices have been specifically designed to
deliver each class of inhaled drugs to patients, the choice of
both drugs and device should be individualized in order to
maximize the clinical benefit [1–3].
Technological innovations in inhaler devices have improved
their efficiency in lung deposition up to 40% of the nominal dose,
compared with 10–15% that was achieved in the past [4]. The
high technological performances of drug formulation and inha-
lers can be totally wasted if these devices are not correctly used
or inhaled according to the health-care provider instruction. In
the real world, physicians and patients struggle to master the
appropriate inhalation technique: among patients, errors in inha-
lation technique and medication delivery occur in 20–80% inha-
ler users [5] and among physicians, only 10–52% demonstrate
adequate knowledge of the proper device use [5]. Less than 20%
of patients are fully adherent with their inhaled therapy [6]. The
most common clinically significant errors, irrespective of the type
of inhaler, are not making an exhalation before each inhalation
and no breath holding at the end [7]. Not inhaling as fast as
possible [7] and not using a slow inhalation [8] are also clinically
important for dry powder inhalers (DPIs) and pressurized
metered-dose inhalers (pMDIs), respectively.
The increasing complexity of inhalers contributes to
improve the clinical advantages, but unavoidability amplifies
the problems associated with their use [5]. Therefore, standar-
dized and simplified techniques for the use of inhalers in the
treatment of asthma and COPD should be proposed [3], with
the aim to limit the misuse of inhalers and improve the proper
medication delivery and treatment [9]. Furthermore, adher-
ence is also important [1,2] and low adherence is related to
poor control [10]. This can be improved by counseling linked
to feedback and patient satisfaction with their inhaler [10,11].
This literature search in Pubmed includes the main evi-
dence on DPI features that may affect their use and the clinical
benefit of patients. Data from clinical trials were considered,
when available, as well as real-world evidence. The review
examined technological and training issues associated with
the use of DPI in clinical practice, focussing on features of
the Easyhaler device.
2. Dry powder inhalers (DPIs)
DPIs have been designed to reproducibly deliver a predefined
dose of the drug to the airways of the lung. The portion of the
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inhaled dose that can reach and deposit in the airways to
exert its local clinical effects, contains aerosol particles in the
fine-particle fraction range of 1–5 µm [3]. The mass of these
particles, in the emitted dose, within this size range, is known
as the fine-particle dose (FPD). The FPD varies widely among
inhalers, with 12–35% for DPIs, 10–50% for pMDIs, and
30–50% for the soft mist inhaler [12–14]. A fast inhalation is
clinically important [7] when using a DPI because these
devices utilize the interaction between the patient’s inhalation
flow and the internal resistance of the inhaler to provide a
turbluent airflow energy that de-aggregates (break-up) their
drug formulations [15–18]. Figure 1 shows that the resistance
of DPIs ranges from low to high. This figure shows that to
achieve a set turbulent airflow energy, for example, an energy
equivalent to a pressure change of 4 kPa, the higher the
resistance then the lower is the required peak inhalation
flow (PIF). The higher the resistance then the lower is the inter-
patient variability of PIF [17]. Also, when patients use different
inhalers with the same inspiratory effort the PIF is lower and
the turbulent airflow energy is higher through DPIs with high
resistance compared to those with low resistance [17]. In
simple words, for the patient to receive the targeted treat-
ment dose, with a high-resistance inhaler device a low PIF
through the inhaler is enough, while with low resistance
devices a higher PIF is required. This is highlighted in Figure
1 and explains why the Handihaler, that has the highest
resistance, is widely used by COPD patients, regardless of the
severity of their disease or the PIF that they can achieve [19].
An ideal device should be easy to use since this improves the
inhalation technique as well as patient’s acceptance and prefer-
ence [10,20]. The consistency in the fine-particle dose, the perfor-
mances regardless of inhalation flow, safety, and efficacy are other
important parameters that should be considered in the choice of
an inhaler [16].
3. How to overcome common technical mistakes in
DPI use
Although DPIs were introduced to overcome the difficulties
between inhaler actuation and inspiration [21], in their study
on a total of 2288 records of inhaler technique Melani et al.
showed that critical mistakes in the use of DPI were common
with all kind of devices and were associated with older age
(p = 0.008), lower schooling (p = 0.001), and lack of training
on inhaler technique (p < 0.001).
The consequences of DPI incorrect use are clinically very
relevant, with a significant increased risk of hospitalization,
emergency room visits, courses of oral steroids and antimicro-
bials and poor disease control [21]. Therefore, inhaler
Article highlights
● Pharmacological therapy for asthma, chronic obstructive pulmonary
disease (COPD), and asthma/COPD overlap should control symptoms,
reduce the frequency and severity of exacerbations, improve exercise
tolerance and the health status, and reduce mortality. The choice of
both drugs and inhalers should be individualized to maximize the
clinical benefit.
● An ideal inhaler should be easy-to-use as well as patient’s acceptance
and preference.
● Dry powder inhalers have been designed to reproducibly deliver
a predefined dose of the drug to the airways of the lung.
● During an inhalation, a turbulent airflow energy is generated inside
a DPI by the interaction between the inhaler’s resistance and the
inhalation flow. This energy deaggregates the formulation of the
metered dose to provide a fine particle dose that is deposited into
the airways.
● When patients use a DPI with the same inspiratory effort, the peak
inhalation flows are lowest through an inhaler with high resistance
and highest through those with low resistance. The resulting turbu-
lent airflow energy is higher in DPIs with higher resistance.
● Easyhaler®, a multiple-dose DPI, demonstrates similar clinical efficacy
to pMDIs and other DPIs and patients have no difficulties in using it.
● The consistency in the fine-particle dose, the performances regardless
of inhalation flow, safety, and efficacy are other important para-
meters that should be considered in the choice of an inhaler. The
Easyhaler meets these criteria.
Figure 1. Dry powder inhaler resistance and optimal peak inhalation flow for correct drug delivery [Reproduced with permission from ref [18]].
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technique training to minimize errors is essential. Guidelines
for asthma [1] and COPD [2] highlight the importance of
patients’ education and recommend that any new inhaler
device should not be prescribed without a deepened training
by health professionals who should illustrate the correct
use [22].
Different levels of training – intuitive use without instruc-
tions, after reading the patient information leaflet and after
health-care professional’s instruction – were used to instruct
patients to use inhalers from several manufacturers; the per-
centage of patients who correctly used the inhaler differen-
tiated across the levels of training and across the devices [23].
Only when trained by health-care professionals, 95% of
patients achieved device use mastery and used correctly the
inhaler, independently of the kind of device proposed [23].
That instruction should be, however, followed up by addi-
tional visits confirming adequate performance with the
inhaler.
4. Easyhaler®: technical performances and
therapeutic efficacy
The Easyhaler® is a multiple-dose DPI developed by Orion
Pharma (Espoo, Finland) for the administration of monothera-
pies salbutamol, beclometasone, budesonide, formoterol, and,
combination therapies; salmeterol-fluticasone, and budeso-
nide-formoterol. Like the Turbuhaler, resistances of the
Easyhaler combination therapies are lower than the mono-
therapies (Figure 1). The resistance of the budesonide-
formoterol Easyhaler is classified as medium/high, as that of
the budesonide-formoterol Turbuhaler. This is why inhalation
flow rates through the budesonide-formoterol Easyhaler are
similar to those through the budesonide-formoterol
Turbuhaler [24]. Furthermore, Easyhaler® was compared with
a conventional metered-dose inhaler, demonstrating similar
clinical efficacy and no difficulties in using it [25].
4.1. Dose uniformity and evaluation of flow rate
The effectiveness of an inhaled treatment may be compro-
mised if the inhalation does not deliver a uniform dose of the
drug. Storage temperature and humidity, device handling, and
variations in inhalation flows are potential factors that may
affect the uniformity of the delivered dose [26]. Easyhaler® has
been tested in different environmental conditions that simu-
lated real-world situations – significant temperature and
humidity variations, dropping, and after vibration to investi-
gate its consistency in delivered dose uniformity. All these
conditions did not modify the uniformity of the delivered
dose that remained consistent when different inhalation
flows (31, 43, 54 L/min) were applied [26]. Inhalation flow
parameters using Easyhaler® were evaluated in 187 patients
with asthma and COPD. The mean PIF was 64 L/min, ranging
from 35 to 101 L/min, in 143 asthmatic patients (age range -
6–82 years) and 56 L/min, ranging from 27 to 83.7 L/min, in 44
COPD patients (47 to 80 years old). In-vitro studies, using the
10th, 50th and 90th percentile of these patient PIF results,
revealed that there was only a small inhalation flow rate
dependent dose emission effect, as shown in Figure 2, Panel
A [18]. Over a range of PIF values, which are representative of
patient use, the dose emission of budesonide and formoterol
was even more consistent than that achieved by Turbuhaler
(Figure 2 Panel B). Even at the 10th percentile inhalation flow,
the delivered and fine particle doses were 98% and 89%–93%
of those emitted from the median PIF [18]. Therefore, the dose
delivered to the lung using Easyhaler® is not exclusively deter-
mined by patients’ inhalation flow and dosing consistency is
guaranteed across a wide range of inhalation flows, from 30 L/
min to 60 L/min, as often reported for asthmatic children and
COPD patients [20].
Dose emission studies using real-life patient inhalation pro-
files show that not all of the metered dose is emptied from
some DPIs during inhalation [27]. This is due to insufficient
inhaled flow and volume passing through the dosing cup of
Figure 2. Comparison of two budesonide/formoterol DPIs 160/4.5 µg/dose, Easyhaler (a) and Turbuhaler (b) regarding the consistency of the delivered dose at
different inhalation flow rates [Reproduced with permission from ref [18]].
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the device. It has been shown that an inhaled volume of
750 ml is sufficient to empty all the metered dose from the
dosing cup of the Easyhaler [28] and that the majority of
patients, regardless of age and disease severity exceed this
volume when they inhale through the Easyhaler [17,24]. The
Easyhaler cross section, in Figure 3, reveals why only a small
inhaled volume is required to deliver all the measured dose
out of the dosing cup. This figure also shows the airtight
reservoir, containing the inhaler’s formulation, that protects
the product from moisture such that dose delivery is unaf-
fected by adverse storage conditions [26]. When the patient
presses the top of the Easyhaler, a click is heard and the filled
dosing cup rotates to place the metered dose at the inlet of
the inhalation channel, next to the air intake vent. If the
patient clicks twice or more, the unused powder falls to the
chamber at the bottom of the device and will not be available
for further dosing. Hence, only one dose is available for inha-
lation irrespective of the number of clicks/actuations.
Figure 3 shows that when the patient inhales through the
Easyhaler, the inhaled air enters the device through the air
inlet vent and is directed into the dosing cup where the
metered dose is entrained into the inhaled airstream. Next,
the airstream is lead to the aerosolization engine where the
narrower flow channel leads to acceleration of the flow rate.
Typical flow rates are 70 m/s in the aerosolization engine
slowing down to 35 m/s at the exit according to computa-
tional fluid dynamics simulation [24]. This accelerated flow
combined with wall collisions in the aerosolization engine
produces a very efficient de-aggregation of the dose leading
to a high and consistent FPD, which is only marginally affected
by the patient’s inhalation flow rate [24]. A PIF 30 L/min or
higher is enough to efficiently disaggregate the dose in the
Easyhaler® [17]. This PIF through the Easyhaler® can be easily
achieved by both children with asthma and COPD patients
[17]. Furthermore, the resistance in the Easyhaler contributes
to a lower interpatient variability of PIF values and turbulent
airflow energy [17] which leads to low inter- and intra-
variation in the dose emission, with respect to the fine-
particle delivery [20]. This aspect is extremely important from
a clinical point of view since the valuable pharmaceutical
performance of a device is given by the consistency between
doses and the closeness to the labeled dose.
4.2. Equivalence between budesonide-formoterol
Easyhaler and Turbuhaler
Budesonide-formoterol fumarate dihydrate is one of the most
well documented of inhaled corticosteroids (ICS) + Long-
acting β-agonists (LABAs) combinations currently on the mar-
ket. This combination shows an increased anti-inflammatory
activity and higher efficacy over time in achieving asthma
control at a lower total dose of budesonide [29]. The rapid
onset of action from formoterol could improve FEV1 after 5
min from inhalation in asthmatic patients [30]. In MART
(Maintenance and Reliever Therapy), for patients with asthma
treatment administered by a single inhaler, formoterol quickly
reduces symptoms and contributes to achieve asthma control
[31]. Budesonide-formoterol Easyhaler® has been shown to be
bioequivalent with the reference product budesonide-
formoterol Turbuhaler® on both efficacy and safety [32,33]
4.3. Clinical effectiveness and safety
In real-life, the effectiveness of budesonide-formoterol
Easyhaler® was evaluated in a post-authorization efficacy
assessment study, enrolling 2200 asthmatic outpatients. The
percentage of patients with well-controlled asthma (ACT score
20–25 points) increased from 46.6% at the first visit to 90.8%
at the third visit, while the percentage of patients with poor
control of asthma (ACT score less than 15 points) decreased
from 14.9% to 1.2%. The adherence rate increased from 88%
at the first visit to 95.3% at the third visit [34]. Tamasi and
coworkers [35] have shown that, in a real-world setting, most
patients with obstructive airway disease, asthma, COPD or
Figure 3. Easyhaler features for consistent dose emission. Cross-section of the Easyhaler® with a schematic design to explain how the fine-particle dose is generated
during inhalation [Adapted from ref [20]].
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ACO, treated with fixed combinations of inhaled bronchodila-
tors and steroids, and switched from their current inhaler to
the Easyhaler®, achieved a better control of the disease, after 3
months from the switching. Of note, most patients considered
the Easyhaler® as portable, easy to learn and use and to keep
clean device, during daily activities [35]. Both disease control
and the quality of life improved, Easyhaler® was considered
easy to use and most patients were satisfied with the device
[35]. Other studies in real practice described Easyhaler® as easy
to teach by clinicians and easy to use, and patients’ satisfac-
tion with the device was always high [36].
4.4. Switching device to improve adherence
Switching a patient from one inhaler to another should be
accompanied by face-to-face consultation to minimize possi-
ble inhalation mistakes, due to technical differences among
the various devices [37]. In Swedish primary care, adults with
persistent asthma switched from budesonide/formoterol
Turbuhaler® to budesonide/formoterol Easyhaler® and showed
equivalent or better disease control after switching [38]. In
real-life, Price et al. [39] compared clinical outcomes of
patients (adults and children) who remained using the same
inhaler or switched to Easyhaler®. They showed that 65.7% of
patients who switched to Easyhaler® received a face-to-face
consultation at the index prescription date, thus suggesting
the feasibility of a correct training even in children. Compared
to patients who maintained their same inhalers, patients who
switched to Easyhaler® gained a higher overall asthma control
(OR 1.26, 95% CI 1.05–1.52), and showed non-inferior risk
domain asthma control -no asthma-related hospitalization,
acute oral steroid use, or lower respiratory tract infection
and exacerbation rate [39]. Although mean asthma-related
health-care costs increased from baseline to outcome years
in both groups, the costs of drugs (SABA) increased signifi-
cantly more in patients who used other inhalers than in those
who switched to Easyhaler® (mean difference £5.5/patient/
year) and, consistently, consultation costs decreased signifi-
cantly (mean difference £13.5/patient/year) [39]. Therefore,
choosing the most appropriate inhaler for each patient is
essential to achieve good clinical outcomes and optimize
health-care resources. During switching, the patient should
be involved and trained to avoid more frequent visits to the
clinic for training and support and negative impacts on dis-
ease outcomes, resulting in higher short- and long-term
health-care costs [40,41]. Furthermore, Muller et al. showed
that Easyhaler was preferred by most patients and its use as
simpler as and more effective than the use of a pMDI [42].
5. Conclusion
Guidelines for asthma and COPD consistently recommend that
clinicians instruct patients in the use of their inhaler and
regularly check the correctness of inhalation technique.
However, it is not clear how this continuous training could
be maintained. First of all, significant efforts are required to
persuade patients about the importance of a correct inhala-
tion procedure and adherence in face-to-face counseling
before prescribing inhaled therapy.
The Easyhaler® is easy-to-use, and patients can be trained
with reading the manufacturer’s instructions. It has added
design features, such as the protective case and dose counter
that further facilitate its use, as confirmed by the proven
patient acceptance. In addition, regardless of the age of
patients and how the device is used, Easyhaler® provides
a consistent and accurate drug delivery; this is valuable since
any clinical change is related to asthma control rather than to
wrong dosing. There is a misconception about DPI resistance
because low inhalation flows through a DPI with high resis-
tance are comparable to high inhalation flows through a DPI
with low resistance. The internal resistance of budesonide-
formoterol combination Easyhaler® is medium-high, as is that
of budesonide-formoterol Turbuhaler hence inhalation flows
achieved by patients through these two DPIs are relatively
similar. This level of resistance in the Easyhaler and its internal
design ensure complete deaggregation of the dose even at
low peak inhalation flows (30 l/min and above). This inhalation
flow can be achieved by children with asthma, adults with
asthma and COPD patients regardless of the severity of their
disease.
6. Expert opinion
Mistakes in the use of inhalers limit the clinical benefit, and
so significant efforts are required to educate patients about
the importance of a correct inhalation procedure and adher-
ence. The easier the inhaler is to use, then the incidence of
inhaler technique errors is reduced and the lesser the dose is
affected by the patient’s inhalation flow then the more con-
sistent is the delivery of the emitted dose. Dry powder inha-
lers have different degrees of resistance such that when
patients use one with a high resistance their inhalation
flows are lower than when they use an inhaler with low
resistance.
Among DPI currently available on the market, Easyhaler® is
easy-to-use, and so patients can be trained with reading the
manufacturer’s instructions. Also, regardless of the age of
patients and how the device is used, it provides a consistent
and accurate drug delivery. The resistance of the budesonide-
formoterol Easyhaler is classified as medium/high, which is
similar to that of the budesonide-formoterol Turbuhaler. This
means that inhalation flow rates through the budesonide-
formoterol Easyhaler are similar to those through the budeso-
nide-formoterol Turbuhaler. The degree of resistance in the
Easyhaler contributes to a lower interpatient variability of peak
inhalation flow and turbulent airflow energy which leads to
the low inter- and intra-variation in the dose emission. In real-
life, the effectiveness of budesonide-formoterol Easyhaler® has
been evaluated in a post-authorization efficacy assessment
study, enrolling 2200 asthmatic outpatients. The results of
this study indicated that the percentage of patients with well-
controlled asthma increased and even after three visits the
majority of patients achieved asthma control. The majority of
patients even considered the Easyhaler® as portable, easy to
learn and use and to keep clean device, during daily activities;
both disease control and the quality of life improved and
patients were satisfied with the device.
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